Patient information guide

Osteoporosis in men and fracture risk

A DXA scan measures bone density. Fracture risk also depends on previous injuries and other health factors. Testosterone testing answers a separate question.

Three different assessments
DXA
Bone mineral density, usually at hip and spine.
FRAX
Estimates future fracture risk.
Testosterone
Investigates suspected hormone deficiency.
On this page

Osteoporosis is often associated with the years after menopause. Men can also lose bone density and sustain fractures. A hip or spine fracture in older age can have lasting effects on movement and independence.

From a urological perspective, this issue has two important connections. The first is the relationship between testosterone deficiency and bone metabolism. The second is the effect of androgen deprivation therapy applied for prostate cancer on bone health. However, the positive effect of testosterone therapy on bone density does not mean that it has been proven to prevent fractures.

The value of bone health in terms of longevity is based on preventing fractures and loss of function rather than improving a laboratory score alone.

Causes of bone loss in men

Bone tissue is renewed throughout life. Osteoblasts are involved in bone formation, and osteoclasts are involved in bone destruction. The balance of these processes is affected by age, hormones, nutrition, physical load and diseases.

Decreasing the amount of bone and deteriorating its microarchitecture can make the bone more prone to fracture. The clinical significance of osteoporosis is therefore not only a low measurement of bone density. Fractures that occur as a result of a low-energy fall or a milder strain are among the important consequences of the disease.

In addition to advanced age, glucocorticoid use, hypogonadism, some intestinal diseases, malnutrition, smoking and alcohol exposure, previous fractures, and certain chronic diseases may contribute to the development of osteoporosis in men. Androgen suppression in prostate cancer treatment is also a separate risk factor.

Bone loss does not always cause pain. The first obvious sign may be a spinal, wrist or hip fracture. Height shortening and newly developed kyphotic posture may also suggest vertebral fractures in some patients.

Testosterone and bone health

Estradiol, which is formed by the conversion of testosterone and a part of it through aromatase, plays a role in male bone metabolism. In particular, the role of estrogen signaling in male bone tissue shows that bone risk cannot be explained by looking only at total testosterone levels.

Bone mineral density may decrease in some men with significant hypogonadism. However, a direct relationship between mildly low testosterone levels and osteoporosis cannot always be demonstrated. Obesity, age and accompanying diseases also affect both hormone measurements and bone health.

The EAU 2026 hypogonadism guideline addresses the evaluation of bone mineral density and management of osteoporosis with standard methods in people with severe hypogonadism and fracture risk. (EAU Guidelines on Male Hypogonadism)

Do all men with low testosterone have osteoporosis?

No. Hypogonadism is a risk factor for bone health, but by itself it does not diagnose osteoporosis. Similarly, not every man with osteoporosis has testosterone deficiency.

If there are clinical symptoms, total testosterone is measured under appropriate morning conditions and low values are confirmed. Bone risk assessment should also include previous fractures, bone density, and other clinical factors.

Measuring bone density

Dual-energy X-ray absorptiometry (DXA) is the main imaging method used to evaluate bone mineral density. Measurements are usually made in the lumbar spine and hip areas.

The T-score obtained by DXA indicates how much the measured bone density deviates from the young adult reference population. A T-score of −2.5 or below in men in the appropriate age group is one of the criteria used in the definition of osteoporosis.

However, the same score and interpretation rules do not apply at all ages. Especially in men under the age of 50, Z-score and evaluation of secondary causes become important. Moreover, in high-risk cases such as a history of hip or spine fracture, the treatment decision is not reduced only to the DXA result.

At what age should men have DXA?

Some clinical guidelines for men recommend DXA evaluation around age 70 or later. In the 50–69 age group, it recommends earlier measurement based on previous low-trauma fractures, hypogonadism, long-term glucocorticoid use and other risk factors. The international DXA application guide published in 2025 also evaluates measurement in men over the age of 70 and those with risk factors over the age of 50. (Updated practice guideline for dual-energy X-ray absorptiometry, 2025)

This does not mean that all men have to have DXA at the same age and at the same intervals. The screening decision to be implemented in Türkiye should be made together with the relevant clinical recommendations and the person’s risk profile.

Estimating fracture risk with FRAX

FRAX is a tool that provides a prediction of the likelihood of major osteoporotic fractures and hip fractures over the next decade using specific clinical risk factors. Under appropriate conditions, the femoral neck bone density result can also be included in the calculation.

The result supports monitoring and treatment decisions based on fracture risk, along with age and other findings.

It is important to use a country-adapted risk model in the FRAX assessment. It may not be correct to directly transfer treatment thresholds established for a country to patients in Türkiye.

Additionally, FRAX does not fully reflect all risks. The risk also needs to be evaluated clinically, especially in some men who fall frequently, have significant sarcopenia, or are receiving androgen deprivation therapy for prostate cancer. (NOGG Clinical Guideline for the Prevention and Treatment of Osteoporosis, 2024)

Does testosterone treatment prevent fractures?

In this regard, it is necessary to understand that bone density and fracture risk have different outcomes.

Testosterone therapy may increase bone mineral density in some men diagnosed with hypogonadism. However, this change does not prove to reduce clinical fractures.

The TRAVERSE fracture substudy, published in the New England Journal of Medicine in 2024, included 5,204 men aged 45–80 with symptoms of hypogonadism and confirmed low testosterone. Participants had cardiovascular disease or a high risk of developing it.

Over a median follow-up of 3.19 years, clinical fractures occurred in 91 of 2,601 men in the testosterone group (3.50%) and 64 of 2,603 in the placebo group (2.46%). The hazard ratio was 1.43 (95% confidence interval 1.04–1.97). Testosterone did not reduce the frequency of fractures. In this study, clinical fractures were more common in the testosterone group. (Snyder et al., testosterone treatment and fractures, TRAVERSE substudy, 2024)

This result does not indicate that testosterone has no use in suitable hypogonadism patients. However, it makes clear that administering testosterone alone to prevent or treat osteoporosis is not a substitute for established anti-fracture treatments.

A meta-analysis of randomised controlled trials published in 2026 also reported an increased risk of clinical fractures with testosterone replacement. Stated that the increase was especially associated with non-major fractures, and the same result could not be shown for major osteoporotic fractures such as hip and vertebra. (Systematic review and meta-analysis of testosterone replacement and fracture risk, 2026)

What should be the approach in a hypogonadism patient with a high risk of fracture?

The diagnosis of hormone deficiency is confirmed by its own clinical criteria. Osteoporosis and fracture risk are also evaluated. If the risk of fracture is high, the need for proven anti-fracture treatments should be addressed by relevant specialties.

The initiation of testosterone therapy does not make independent evaluation of osteoporosis unnecessary.

Bone health during prostate cancer hormone treatment

Androgen deprivation therapy (ADT) used in prostate cancer aims to control the disease by reducing the effect of testosterone. However, suppression of androgens may also affect bone metabolism.

Therefore, it is important to evaluate bone mineral density and fracture risk in men taking ADT. Duration of treatment, initial fracture risk, other medications used and existing diseases are taken into account.

The 2024 UK NOGG guideline reports that ADT-related bone loss may be evident in the first 6–12 months after starting treatment and the risk of fracture may be increased. (NOGG Clinical Guideline for the Prevention and Treatment of Osteoporosis, 2024)

Some high-risk patients may also require osteoporosis treatment. Here, the choice of bone-preserving therapy should be made based on relevant characteristics, including oncological status and renal functions.

There is an important limit: A man receiving ADT for prostate cancer should not be started on testosterone just because bone loss occurs. Hormonal decisions that will affect cancer treatment should be addressed by the oncological team.

Muscle strength, falls and fracture risk

Bone and muscle health are areas that affect each other. Decreased muscle strength, balance problems and falls can increase the risk of fractures. Therefore, it is insufficient to focus only on the DXA result in elderly men.

Sarcopenia is assessed by measures of muscle strength and physical performance. Osteoporosis is related to bone mineral density, fracture history and related risk factors. They can occur together in the same patient, but one does not replace the other.

Resistance exercises and proper balance training can be helpful in maintaining physical functions. The exercise program should be arranged according to the person’s fracture history, balance status and accompanying diseases.

Vitamin D and calcium

Getting enough calcium from the diet and appropriate evaluation of people with vitamin D deficiency are important for bone health. However, it cannot be said that all men should be given high doses of vitamin D or calcium supplements.

Supplementation decisions should be made carefully, especially in people with kidney stones or chronic kidney disease. Taking too much vitamin D or calcium can lead to other health problems.

In men with osteoporosis, other tests may be requested depending on hemogram, kidney functions, calcium-phosphorus metabolism and appropriate clinical condition within the scope of investigating secondary causes. These do not constitute a single panel that should be applied annually in every healthy man.

Treatment options

The goal of treatment for osteoporosis is to prevent new fractures and, when possible, improve bone health. Depending on the risk of fracture, bisphosphonates, denosumab or, in certain high-risk cases, anabolic bone treatments may be considered.

Treatment selection is made based on the patient’s kidney functions, previous fractures, cancer history and other clinical characteristics. The effectiveness and side effect profiles of osteoporosis drugs differ from each other. For this reason, it is not appropriate to apply a medication or hormone program obtained from the internet based solely on a low T-score.

The 2024 evidence-based European guideline on male osteoporosis centers on assessment and treatment based on fracture risk. (Evidence-based guideline for the management of osteoporosis in men, 2024)

When bone health should be assessed

Bone health may require separate evaluation in men who have suffered a low-trauma fracture, have significant height reduction, have severe hypogonadism, have been using glucocorticoids for a long time, or are receiving ADT for prostate cancer.

The mere presence of fatigue or lack of sexual desire in a person does not directly mean a diagnosis of osteoporosis. The scope of clinical investigation should be determined by actual risks.

The place of bone health in the Longevity approach is the goal of reducing fractures and related loss of movement. Increasing testosterone alone does not indicate that this goal has been achieved.

Common questions

At what age does osteoporosis begin in men?

It does not start at the same age in every man. Advanced age is an important risk factor. However, hypogonadism can also be seen at younger ages due to medication use or chronic diseases.

Does testosterone deficiency cause osteoporosis?

Severe hypogonadism may be associated with decreased bone density. However, not every low testosterone level means osteoporosis. Other reasons are also evaluated.

Does testosterone prevent bone fractures?

In the 2024 TRAVERSE randomised fracture substudy, testosterone treatment did not reduce clinical fractures, and fracture incidence was higher in the testosterone group.

At what age should men have DXA?

Some guidelines recommend evaluation in men over the age of 70 and in men with risk factors after the age of 50. Personal fracture history and clinical circumstances may alter the age of onset.

Does prostate cancer hormone therapy weaken bones?

Androgen deprivation therapy may be associated with an increased risk of bone loss and fracture. Bone health assessment may be required before treatment and at follow-up.

Is testosterone the only treatment for osteoporosis?

No. There are separate osteoporosis treatments that have been shown to reduce the risk of fracture. Testosterone therapy should not be used instead.


If low testosterone is suspected, the hypogonadism guide explains the symptoms with which hormone measurements are evaluated.

Related reading

This content has been prepared for general medical information purposes. Monitoring osteoporosis, hypogonadism, and bone problems associated with prostate cancer treatment requires individual evaluation. Drug and hormone treatments should not be administered without clinical indication.

Sources6 sources

Cookies required for site functions are always on. You can choose the other categories.

CallWhatsAppAppointment